by | Aug 1, 2026
Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Bright, H. R. B., Smith, C. H., Laws, P., Reynolds, N. J., Phan, D. B., Lunt, M., Warren, R. B....
by admin | Jul 16, 2026
Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology, and Application of the Basophil Activation TestChauhan, J., Vlasova, S., Chenoweth, A., Josephs, D. H., Bax, H. & Karagiannis, S. N., 16 Jul 2026, (Accepted/In press) In: Allergy:...
by | Jul 1, 2026
Genetic proxies of glucagon-like peptide-1 receptor expression are associated with lower risk of psoriasis and psoriatic arthritisRamessur, R., Arham, A. G. A., Saklatvala, J., Thomas, L., Brumpton, B. M., Hoff, M., Videm, V., Åsvold, B. O., Shin, D. B., Kim, D.,...
by | Jul 1, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators RegisterPhan, D. B., Laws, P., Smith, C. H.,...
by | Jun 23, 2026
Melittin in AllergoOncology: From Honey Bee Venom to Anti-Cancer Therapeutic Innovation-An EAACI Position PaperJimenez-Rodriguez, T.-W., Ahmetaj, L., Alfaya Arias, T., Boni, E., Bugadze, L., Chauhan, J., De Las Vecillas, L., Ferastraoaru, D., Izquierdo, E.,...